Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial – The Lancet Invited Commentary: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet Related: WHO issues emergency use approval for India’s Covaxin.   Commentary on Twitter NEW—Interim data from a phase […]

The post RCT: BBV152 (India’s COVAXIN) has an overall vaccine efficacy of 77.8% against symptomatic Covid-19 in adults. appeared first on Links Medicus.